Adherence, compliance and persistence to oral antineoplastic therapy: A review focused on chemotherapeutic and biologic agents

Expert Opinion on Drug Safety

Volumn 11, Issue SUPPL. 1, 2012, Pages

  Gebbia, Vittorio ^a,c   Bellavia, Giuseppe ^a,c   Ferra, Francesco ^b   Valerio, Maria Rosaria ^a,d  

^a UNIVERSITY OF PALERMO   (Italy)

^b Ospedale San Vincenzo   (Italy)

^c LA MADDALENA CANCER CENTER   (Italy)

^d UNIVERSITY OF PALERMO   (Italy)

Author keywords

Adherence; Cancer; Oral chemotherapy; Persistence

Indexed keywords

ALLOPURINOL; ANTINEOPLASTIC AGENT; BIOLOGICAL PRODUCT; CAPECITABINE; CHLORAMBUCIL; CYCLOPHOSPHAMIDE; DEXAMETHASONE; ERLOTINIB; GEFITINIB; IMATINIB; MERCAPTOPURINE; PREDNISONE; TAMOXIFEN; TEMOZOLOMIDE;

ADVANCED CANCER; ANXIETY; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER PATIENT; COLORECTAL CANCER; CONSTIPATION; DEPRESSION; DIARRHEA; DOCTOR PATIENT RELATION; FATIGUE; HEALTH CARE PERSONNEL; HODGKIN DISEASE; HOSPITALIZATION; HUMAN; INSOMNIA; LUNG NON SMALL CELL CANCER; MEDICAL EDUCATION; MEDICAL LITERATURE; MUCOSA INFLAMMATION; NAUSEA; NEOPLASM; NONHODGKIN LYMPHOMA; PAIN; PATIENT COMPLIANCE; PATIENT EDUCATION; REVIEW; SIDE EFFECT; SOCIOECONOMICS; TREATMENT DURATION; TREATMENT OUTCOME;

ADMINISTRATION, ORAL; ANTINEOPLASTIC AGENTS; HEALTH CARE COSTS; HOSPITALIZATION; HUMANS; IMMUNOLOGIC FACTORS; MEDICATION ADHERENCE; NEOPLASMS; SOCIOECONOMIC FACTORS;

EID: 84858671499     PISSN: 14740338     EISSN: 1744764X     Source Type: Journal    
DOI: 10.1517/14740338.2011.645803     Document Type: Review

References (83)

1. Ruddy K, Mayer E, Partridge A. Patient adherence and persistence with oral anticancer treatment. CA Cancer J Clin 2009;59:56-66
2. Weingart SN, Brown E, Bach PB, et al. NCCN Task Force Report: oral chemotherapy. J Natl Compr Canc Netw 2008;6(Suppl 3):S1-14 (Pubitemid 351497279)
3. Fleming TR, Mets DL. Surrogate end point in clinical trials. Ann Intern Med 1996;125:605-13
4. Chassany O, Sagnier P, Marquis P, et al. Patient-reported outcomes: the example of health-related quality of life-a European guidance document for the improved integration of health-related quality of life assessment in the drug regulatory process. Drug Inf J 2002;36:209-38 (Pubitemid 34208219)
5. Liu G, Franssen E, Fitch MI, et al. Patient preferences for oral versus intravenous palliative chemotherapy. J Clin Oncol 1997;15:110-15 (Pubitemid 27021524)
6. Borner MM, Schoffski P, de Wit R, et al. Patient preference and pharmacokinetics of oral modulated UFT versus intravenous fluorouracil and leucovorin: a randomized crossover trial in advanced colorectal cancer. Eur J Cancer 2002;38:349-58 (Pubitemid 34121962)
7. Wojtacki J, Wiraszka R, Rolka-Stempniewicz G, et al. Breast cancer patients' preferences for oral versus intravenous second-line anticancer therapy. Eur J Cancer 2006;159:abstract 381
8. Paley M, Love N, Carlson R, et al. Preferences for oral and parenteral antitumor therapy: a survey of 260 patients with metastatic breast cancer. Proc Am Soc Clin Oncol 2005;23:619
9. Jensen LH, Osterlind K, Rytter C. Randomized cross-over study of patient preference for oral or intravenous vinorelbine in combination with carboplatin in the treatment of advanced NSCLC. Lung Cancer 2008;62:85-91
10. Kohne CH, Folprecht G. On prejudice and facts and choices. Ann Oncol 2006;17:185-7 (Pubitemid 43160104)
11. McLeod HL, Evans WE. Oral cancer chemotherapy: the promise and the pitfalls. Clin Cancer Res 1999;5:2669-71 (Pubitemid 29493936)
12. Gebbia V, Puozzo C. Oral versus intravenous vinorelbine: clinical safety profile. Expert Opin Drug Saf 2005;4:915-28 (Pubitemid 41246141)
13. Molassiotis A, Brearley S, Sauders M, et al. Effectiveness of a home care nursing program in the symptom management of patients with colorectal and breast cancer receiving oral chemotherapy: a randomized, controlled trial. J Clin Oncol 2009;27:6191-8
14. Partridge AH. Non-adherence to endocrine therapy for breast cancer. Ann Oncol 2006;17:183-4 (Pubitemid 43160103)
15. Findlay M, von Minckwitz G, Wardley A. Effective oral chemotherapy for breast cancer: pillars of strength. Ann Oncol 2007;19:212-19
16. Rand CS. Measuring adherence with therapy for chronic diseases: implications for the treatment of heterozygous familial hypercholesterolemia. Am J Cardiol 1993;72:68D-74D (Pubitemid 23286506)
17. Osterberg L, Blaschke T. Adherence to medication. N Engl J Med 2005;353:487-96
18. Haynes RB, Taylor DW, Sackett DL. Compliance in Health Care. Johns Hopkins University Press; Baltimore: 1979
19. Sabate E. Adherence to long-term therapies. Evidence form action. World Health Organization (WHO); Geneva: 2003
20. Cramer JA, Roy A, Burrell A, et al. Medication compliance and persistence: terminology and definitions. Value Health 2008;11:44-7 (Pubitemid 351160875)
21. Rudd P. In search of the gold standard for compliance measurement. Arch Intern Med 1979;139:627-8 (Pubitemid 10135247)
22. Levine AM, Richardson JL, Marks G, et al. Compliance with oral drug therapy in patients with hematologic malignancy. J Clin Oncol 1987;5:1469-77
23. Evans L, Spelman M. The problem of non-compliance with drug therapy. Drugs 1983;25:63-76 (Pubitemid 13169457)
24. Tebbi CK. Treatment compliance in childhood and adolescence. Cancer 1993;71(10 Suppl):3441-9 (Pubitemid 23148540)
25. Gauthier DK, Turner JG, Langley LG, et al. Monitoring universal precautions: a new assessment tool. Infect Control Hosp Epidemiol 1991;12:597-601
26. Urquhart J. Role of patient compliance in clinical pharmacokinetics. A review of recent research. Clin Pharmacokinet 1994;27:202-15 (Pubitemid 24280233)
27. Festa RS, Tamaroff MH, Chasalow F, Lanzkowsky P. Therapeutic adherence to oral medication regimens by adolescents with cancer. I. Laboratory assessment. J Pediatr 1992;120:807-11
28. Haynes RB, Taylor DW, Sackett DL, et al. Can simple clinical measurements detect patient noncompliance? Hypertension 1980;2:757-64 (Pubitemid 11180123)
29. Choo PW, Rand CS, Inui TS, et al. Validation of patient reports, automated pharmacy records, and pill counts with electronic monitoring of adherence to antihypertensive therapy. Med Care 1999;37:846-57
30. Partridge AH, Archer L, Kornblith AB, et al. Adherence and persistence with oral adjuvant chemotherapy in older women with early-stage breast cancer in CALGB 49907: adherence companion study 60104. J Clin Oncol 2010;28:2418-22
31. Avorn J, Monette J, Lacour A, et al. Persistence of use of lipid-lowering medications: a cross-national study. J Am Med Assoc 1998;279:1458-62 (Pubitemid 28228203)
32. Tindall WN, Boltri JM, Wilhelm SM. Mild-to-moderate ulcerative colitis: your role in patient compliance and health care costs. J Manag Care Pharm 2007;13:S2-S12
33. Waterhouse DM, Calzone KA, Mele C, et al. Adherence to oral tamoxifen: a comparison of patient self-report, pill counts, and microelectronic monitoring. J Clin Oncol 1993;11:1189-97 (Pubitemid 23163362)
34. Veronesi A, Pizzichetta MA, Ferlante MA, et al. Tamoxifen as adjuvant after surgery for breast cancer and tamoxifen or placebo as chemoprevention in healthy women: different compliance with treatment. Tumori 1998;84:372-5 (Pubitemid 28313359)
35. Osborne CK. Tamoxifen in the treatment of breast cancer. N Engl J Med 1998;339:1609-18 (Pubitemid 28536137)
36. Smith IE, Dowsett M. Aromatase inhibitors in breast cancer. N Engl J Med 2003;348:2431-42 (Pubitemid 36682823)
37. Bonadonna G, Valagussa P. Dose-response effect of adjuvant chemotherapy in breast cancer. N Engl J Med 1981;304:10-15 (Pubitemid 11212891)
38. Soran A, Nesbitt L, Mamounas EP, et al. Centralized medical monitoring in phase III clinical trials: the National Surgical Adjuvant Breast and Bowel Project (NSABP) experience. Clin Trials 2006;3:478-85
39. Partridge AH, Archer LE, Kornblith AB, et al. CALGB 60104: adherence with adjuvant capecitabine among women age 65 and older with early stage breast cancer treated on CALGB 49907. Presented at the 2008 ASCO Annual Meeting; Chicago, Illinois, Dates; 2008
40. Dezii CM. Medication noncompliance: what is the problem? Manag Care 2000;9:7-12
41. Lebovits AH, Strain JJ, Schleifer SJ, et al. Patient noncompliance with self-administered chemotherapy. Cancer 1990;65:17-22 (Pubitemid 20026803)
42. Haynes RB. A critical review of the "determinants" of patient compliance with therapeutic regimens. In: Sackett DL, Haynes RB, editors. Compliance with Therapeutic Regimens. The Johns Hopkins University Press; Baltimore: 1976. p. 26-39
43. Wang PS, Bohn RL, Knight E, et al. Non-compliance with antihypertensive medications: the impact of depressive symptoms and psychosocial factors. J Gen Int Med 2002;17:504-11 (Pubitemid 34989157)
44. World Helath Organization 2003. Available from: http://whqlibdoc.who.int/ publications/2003/9241545992.pdf p. 1-169
45. Schilsky RL, Hohneker J, Ratain MJ, et al. Phase I clinical and pharmacologic study of eniluracil plus fluorouracil in patients with advanced cancer. J Clin Oncol 1998;16:1450-7 (Pubitemid 28175765)
46. Nixon DW. Special aspects of cancer prevention trials. Cancer 1994;74(9 Suppl):2683-6 (Pubitemid 24319010)
47. Balkrishnan R. Predictors of medication adherence in the elderly. Clin Ther 1998;20:764-1 (Pubitemid 28421497)
48. Cramer JA, Mattson RH, Prevey ML, Ouellette VL. How often is medication taken as prescribed? a novel assessment technique. JAMA 1989;261:3273-7 (Pubitemid 19143549)
49. Llewellyn-Thomas H, Thiel E, McGreal MJ. Cancer patients' evaluations of their current health states: the influence of expectations, comparisons, actual health states and mood. Med Decis Making 1992;12:115-22
50. Bandura A. Self-efficacy: toward a unifying theory of behavioral change. Psychol Rev 1977;84:191-215
51. Kehoe WA, Katz RC. Health behaviors and pharmacotherapy. Ann Pharmacother 1998;32:1076-86 (Pubitemid 28498469)
52. Claxton AJ, Cramer J, Pierce C. A systematic review of the associations between dose regimens and medication compliance. Clin Ther 2001;23:1296-310 (Pubitemid 32804122)
53. Eisen SA, Miller DK, Woodward RS, et al. The effect of prescribed daily dose frequency on patient medication compliance. Arch Intern Med 1990;150:1881-4 (Pubitemid 20316533)
54. Partridge AH, Wang PS, Avorn J. Nonadherence to adjuvant tamoxifen therapy in women with primary breast cancer. J Clin Oncol 2003;21:602-6 (Pubitemid 46621892)
55. Richardson JL, Marks G, Levine A. The influence of symptoms of disease and side effects of treatment on compliance with cancer therapy. J Clin Oncol 1988;6:1746-52 (Pubitemid 19089055)
56. Lee CR, Nicholson PW, Souhami RL, et al. Patient compliance with oral chemotherapy as assessed by a novel electronic technique. J Clin Oncol 1992;10:1007-13
57. Ong LM, de Haes JC, Hoos AM, Lammes FB. Doctor-patient communication: a review of the literature. Soc Sci Med 1995;40:903-18
58. Golin CE, Liu H, Hays RD, et al. A prospective study of predictors of adherence to combination antiretroviral medication. J Gen Intern Med 2002;17:756-65 (Pubitemid 35286241)
59. Kee F. Patients' prerogatives and perceptions of benefit. Br J Med 1996;312:958-60 (Pubitemid 26111792)
60. Claxton AJ, Cramer J, Pierce C. A systematic review of the associations between dose regimens and medication compliance. Clin Ther 2001;23:1296-310 (Pubitemid 32804122)
61. James R, Barni S, von Weikerstahl F, et al. Improving chemotherapy capacity by switching from intravenous to oral vinorelbine: TAMINO, an international time and motion audit. Lung Cancer 2010;67(Suppl 1):S4
62. Fung V, Mangione CV, Huang J, Turk N. Falling into the coverage gap: part D drug costs and adherence for medicare advantage prescription drug plan beneficiaries with diabetes. Health Serv Res 2009;45:355-75
63. Levine AM, Richardson JL, Marks G, et al. Compliance with oral drug therapy in patients with hematologic malignancy. J Clin Oncol 1987;5:1469-76 (Pubitemid 18049881)
64. Sadahiro S, Ohki S, Yamaguchi S, et al. Feasibility of a novel weekday-on/weekend-off oral UFT schedule as postoperative adjuvant chemotherapy for colorectal cancer. UFT Compliance Study Group, Kanagawa, Japan. Cancer Chemother Pharmacol 2000;46:180-4
65. Lee CR, Nicholson PW, Souhami RL, et al. Patient compliance with prolonged low-dose oral etoposide for small cell lung cancer. Br J Cancer 1993;67:630-4 (Pubitemid 23077665)
66. Lee CR, Nicholson PW, Ledermann JA, Rustin GJ. Patient compliance with prolonged oral altretamine treatment in relapsed ovarian cancer. Eur J Gynaecol Oncol 1996;17:99-103 (Pubitemid 26078887)
67. Klein CE, Kastrissios H, Miller AA, et al. Pharmacokinetics, pharmacodynamics and adherence to oral topotecan in myelodysplastic syndromes: a Cancer and Leukemia Group B study. Cancer Chemother Pharmacol 2006;57:199-206 (Pubitemid 41779839)
68. Winterhalder R, Hoesly P, Delmore G, et al. Self-reported compliance with capecitabine: findings from a prospective cohort analysis. Oncology 2011;80:29-33
69. Regnier Denois V, Poirson J, Nourissat A, et al. Adherence with oral chemotherapy: results from a qualitative study of the behaviour and representations of patients and oncologists. Eur J Cancer Care 2010;20:520-7
70. Simons S, Ringsdorf S, Braun M, et al. Enhancing adherence to capecitabine chemotherapy by means of multidisciplinary pharmaceutical care. Support Care Cancer 2011;19:1009-18
71. Weingart SN, Spencer J, Buia S, et al. Medication safety of five oral chemotherapies: a proactive risk assessment. J Oncol Pract 2011;7:2-6
72. Streeter SB, Lee Schwartzberg L, Husain N, Johnsrud M. Patient and plan characteristics affecting abandonment of oral oncolytic prescriptions. J Oncol Pract 2011;7(Suppl 3):46S-51S
73. Gebbia V, Bellavia G, Russo P, et al. Treatment monitoring program implementation of adherence to erlotinib as second-line therapy for advanced non small cell lung carcinoma. Tumori 2010;10:S68
74. Mayer EL, Partridge AH, Harris LN, et al. Tolerability of and adherence to combination oral therapy with gefitinib and capecitabine in metastatic breast cancer. Breast Cancer Res Treat 2009;117:615-23
75. Timmers L, Boons CCLM, Mangnus D, et al. The use of erlotinib in daily practice: a study on adherence and patients' experiences. BMC Cancer 2011;11:284
76. Banna GL, Collova E, Gebbia V, et al. Anticancer oral therapy: emerging related issues. Cancer Treat Rev 2010;36:595-605
77. Viele CS. Managing oral chemotherapy: the healthcare practitioner's role. Am J Health Syst Pharm 2007;64:S25-32 (Pubitemid 46676688)
78. Weingart SN, Flug J, Brouillard D, et al. Oral chemotherapy safety practices at US cancer centres: questionnaire survey. Br Med J 2007;334:407
79. deLemos M. Adherence to therapy with oral agents. J Natl Cancer Inst 2002;94:1652
80. Beney J, Bero LA, Bond C. Expanding the roles of outpatient pharmacists: effects on health services utilization, costs, and patient outcomes. Cochrane Database Syst Rev 2000(3):CD000336
81. Haynes RB, Yao X, Degani A, et al. Interventions to enhance medication adherence. Cochrane Database Syst Rev 2005(4):CD000011
82. McDonald HP, Garg AX, Haynes RB. Interventions to enhance patient adherence to medication prescriptions: scientific review. JAMA 2002;288:2868-79 (Pubitemid 35425073)
83. Hohneker J, Shah-Mehta S, Brandt PS. Perspectives on adherence and persistence with oral medications for cancer treatment. J Oncol Pract 2011;7:65-7